Sonoma Pharmaceuticals
SNOA
14 hedge funds and large institutions have $628K invested in Sonoma Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
13% more capital invested
Capital invested by funds: $555K → $628K (+$73K)
8% more funds holding
Funds holding: 13 → 14 (+1)
0.12% less ownership
Funds ownership: 0.48% → 0.36% (-0.12%)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$55.2K |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$2.92K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$101 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
Bard Associates
Chicago,
Illinois
|
-$41.4K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$10.6K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$101 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $341K | +$55.2K | +548 | +19% |
|
|
BA
2
Bard Associates
Chicago,
Illinois
| $255K | -$41.4K | -411 | -14% |
|
3
BlackRock
New York
| $17K | – | – | – |
|
4
Acadian Asset Management
Boston,
Massachusetts
| $8K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $3K | -$10.6K | -105 | -78% |
|
|
6
Victory Capital Management
San Antonio,
Texas
| $2K | +$2.92K | +29 | New |
|
7
Morgan Stanley
New York
| $1K | – | – | – |
|
8
Osaic Holdings
Scottsdale,
Arizona
| $1K | +$806 | +8 | New |
|
|
RE
9
RBC Europe
London,
United Kingdom
| $10 | – | – | – |
|
|
10
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$2K | -25 | Closed |
|
|
11
Bank of America
Charlotte,
North Carolina
| – | -$101 | -1 | -33% |
|
|
12
Wells Fargo
San Francisco,
California
| – | +$101 | +1 | New |
|
SNOA Hedge Fund Activity: Q1 2020 in Review
14 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q1 2020, worth a combined $628K — up 13% from $555K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SNOA positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $55.2K. The largest seller was Bard Associates, cutting an estimated $41.4K.
- 14 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q1 2020, up from 13 in Q4 2019.
- Funds reported $628K of Sonoma Pharmaceuticals stock for Q1 2020, up 13% quarter-over-quarter.
- 3 funds opened new Sonoma Pharmaceuticals positions in Q1 2020 and 1 closed out, a net change of +2 holders.
- The largest Sonoma Pharmaceuticals buyer in Q1 2020 was Renaissance Technologies, an estimated $55.2K added.
- The largest Sonoma Pharmaceuticals seller in Q1 2020 was Bard Associates, an estimated $41.4K sold.
Based on aggregated 13F filings for Q1 2020.